KADIMASTEM LTD

Their core work

KadiMastem is an Israeli biotech SME specialising in stem cell-based therapeutics, with a scientific core built around induced pluripotent stem cells (iPSCs) and the epigenetic mechanisms that govern cell identity and reprogramming. Their applied work focuses on translating stem cell biology into regenerative medicine products — most visibly in cardiac repair (TECHNOBEAT project) — while their research participation also addresses the fundamental chromatin and methylation dynamics that determine how stem cells differentiate or are reprogrammed. As an industrial partner in academic-led consortia, they bring a drug-development and cell-manufacturing perspective to otherwise science-heavy networks. Their position as an Israeli company in European projects signals experience bridging EU and Israeli innovation ecosystems.

What they specialise in

How they've shifted over time

KadiMastem entered H2020 through TECHNOBEAT (2016–2019), an applied health project focused on cardiac cell therapies — their contribution was product- and application-oriented, with no recorded mechanistic keywords. Overlapping from 2018, EpiSyStem pulled them into the fundamental science behind stem cell identity: epigenetics, chromatin remodelling, and systems biology of reprogramming. This suggests a deliberate move to deepen the scientific foundations of their therapeutic platform, not just deploy it — a pattern common among biotech SMEs seeking to strengthen IP and publication credibility alongside product development.

KadiMastem appears to be building upstream scientific depth in epigenetics and iPSC biology, which typically precedes expanded therapeutic pipeline work — making them a relevant partner for consortia bridging mechanistic stem cell research and clinical translation.

How they like to work

KadiMastem has participated exclusively as a non-coordinating partner in both H2020 projects, indicating a preference — or current scale — suited to contributing specialist capability rather than managing consortia. With 14 distinct partners across 8 countries from just two projects, they engage in mid-to-large European networks rather than bilateral arrangements. This profile fits a biotech SME that joins consortia to access academic science and European networks while offering proprietary cell technology or clinical-development know-how in return.

KadiMastem has built a network of 14 unique partners across 8 countries through two projects, a notably broad reach for an organisation of its size and H2020 tenure. As an Israeli company participating under the EU-Israel association agreement, they add geographic and ecosystem diversity to any European consortium.

What sets them apart

KadiMastem occupies a rare niche as an Israeli biotech SME with hands-on iPSC platform experience operating inside European research consortia — most Israeli cell-therapy companies do not have this EU network footprint. Their combination of an applied therapeutic focus (cardiac, neurological) and genuine epigenetics research engagement means they can credibly participate in both translational health projects and fundamental stem cell science networks. For a consortium coordinator, they offer both proprietary technology access and a non-EU associated-country partner, which can strengthen proposal competitiveness.

Highlights from their portfolio

• TECHNOBEAT
  KadiMastem's largest H2020 award (EUR 649,950) and their entry into European cardiac regenerative medicine networks, signalling their core therapeutic product focus.
• EpiSyStem
  An MSCA Innovative Training Network — participation signals that KadiMastem hosts or co-supervises doctoral researchers, giving them a training and talent-pipeline role beyond purely commercial contribution.